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Abstract 
Diquaternary ammonium gemini Surfactants have emerged as effective gene delivery 
vectors. A novel series of eleven peptide-modified compounds was synthesized, showing 
promising results in delivering genetic materials. The purpose of this work is to elucidate the 
tandem mass spectrometric (MS/MS) dissociation behaviour of these novel molecules 
establishing a generalized MS/MS fingerprint.  
Exact mass measurements were achieved using a hybrid quadrupole orthogonal time-of-
flight mass spectrometer (QqToF-MS) and a multi-stage tandem mass spectrometric analysis was 
conducted using a triple quadrupole-linear ion trap mass spectrometer (QqQLIT-MS). Both 
instruments were operated in the positive ionization mode and are equipped with electrospray 
ionization (ESI). Abundant triply charged [M+H]3+ species were observed in the single stage 
analysis of all the evaluated compounds with mass accuracies of less than 8 ppm in mass error. 
MS/MS analysis showed that the evaluated gemini surfactants exhibited peptide-related 
dissociation characteristics due to the presence of amino acids within the compounds’ spacer 
region. In particular, diagnostic product ions were originated from the neutral loss of ammonia 
from the amino acids’ side chain resulting in the formation of pipecolic acid at the N-terminus 
part of the gemini surfactants. In addition, a charge directed amide bond cleavage was initiated 
by the amino acids’ side chain producing a protonated α-amino-ε-caprolactam ion and its 
complimentary c-terminus ion that contains quaternary amines. MS/MS and MS3 analysis 
revealed common fragmentation behaviour among all tested compounds, resulting in the 
production of a universal MS/MS fragmentation pathway.  
 
Introduction  
Gene therapy has emerged as a promising therapeutic approach for the treatment of 
inherited and acquired genetic disorders. The last few decades have witnessed unprecedented 
interest in developing efficient vectors able to compact, protect and deliver genetic material into 
targeted cells [1, 2]. One particular group is diquaternary ammonium gemini surfactants that 
have been extensively used as non-viral gene delivery vectors [3]. They have the ability to 
package and compact the negatively charged nucleic acids through electrostatic and hydrophobic  
interactions forming nano-sized lipoplexes [4]. Gemini surfactants are composed of two ionic 
head groups attached to their hydrocarbon tails and connected by a spacer (Figure 1A) [5]. The 
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unique structure of gemini surfactants resulted in superior characteristics compared to their 
monomeric counterparts, such as their greater ability in reducing surface tension, lower critical 
micelle concentration (CMC) and lower Krafft temperature (critical micelle temperature) [6]. 
Owing to these enhanced characteristics, lower concentration of gemini surfactants are required 
for gene delivery compared to their monomeric counterparts, thus, they possess lower 
cytotoxicity profile [4]. In addition, gemini surfactants’ distinctive structure offers various 
possibilities for structural modification, allowing for the production of compounds specifically 
designed to overcome delivery barriers. For example, the insertion of pH-sensitive moieties 
resulted in the production of “intelligent” delivery vehicles that respond to the surrounding 
stimuli [7].  
The most widely used group of gemini surfactants is the cationic N, N-
bis(dimethylalkyl)-α,ω-alkane-diammonium surfactants (Figure 1). They were successfully 
utilized in delivering genetic materials both in vitro and in vivo [8, 9]. In fact, Badea et al. 
reported three-fold increase in topical transgene expression in animals treated with N,N'-
bis(dimethylhexadecyl)-1,3-propanediammonium dibromide (designated as 16-3-16) gemini 
surfactant-based nanoparticles compared to animals treated with naked DNA [9]. Despite the 
success of the traditional gemini surfactants, concerns regarding their toxicity have arisen [10]. 
Several approaches have been undertaken to address this problem, including the insertion of 
biocompatible and biodegradable moieties such as sugars, lipids, and amino acids [11-13]. For 
example, glycyl-lysine substituted gemini surfactants exhibited significantly higher gene 
expression in vitro and lower cytotoxicity compared to the unsubstituted parent compound [14-
16]. Moreover, in vivo topical application of the glycyl-lysine substituted gemini surfactant-
based lipoplexes into the rabbit vaginal cavities demonstrated higher transgene efficiency 
compared to the parent compound without visible toxicity [17].  
Although extensive research was focused on the design of new gemini surfactants and 
optimizing their physicochemical properties to increase efficiency and reduce side effects [3, 16, 
18], little is known about their post transfection fate. Many questions remain unanswered 
regarding the degradation profile of nanoparticles after releasing their therapeutic cargo 
including the formation of metabolic by-products, some of which can theoretically be toxic. 
Correlating the biodistribution and the biological fate of the nanoparticles to their chemical 
structure and physicochemical properties can provide insights into the rational design process to 
produce gene carriers with higher efficiency and reduced toxicity. Such knowledge will bridge 
the gap between empirical and rational design. As such, there is a need to develop analytical 
techniques that could identify and quantify gemini surfactants within complex biological 
samples. 
Mass spectrometry (MS) is routinely used for both the quantitative and qualitative 
analysis of pharmaceuticals [19-22]. In our group, we investigated the fragmentation pathways of 
different structural families of gemini surfactants establishing collision induced dissociation-
tandem mass spectrometric (CID-MS/MS) fingerprints for accurate identification of gemini 
surfactants [23-26]. This data was subsequently utilized to develop MS-based methods for the 
quantification of conventional un-substituted gemini surfactants within cells to determine the rate 
of cellular uptake and removal [27-29]. Ongoing research employs the use of these methods to 
investigate subcellular localization and to identify any potential metabolites.  
Recently, a new generation of peptide modified gemini surfactants was introduced 
demonstrating a superior in vitro transfection efficiency compared to the traditional unsubstituted 
gemini surfactants (Figure 1B) [30]. Herein, we aim to evaluate the CID-MS/MS fragmentation 
behaviour of eleven novel peptide modified gemini surfactants. The peptides are attached to the 
spacer region via an amide bond with variable hydrocarbon linkages that may affect the 
efficiency of the developed nano-formulations.  The data from this study will be needed for 
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developing multiple reaction monitoring (MRM) quantification MS/MS methods to probe the 
fate and the biodistribution of topically applied therapeutic gemini surfactant formulations.  
 
Material and methods  
Material  
Eleven novel peptide modified gemini surfactants were synthesized using previously 
reported synthetic methods [16]. Tested compounds were designated as m-7N(R)-m where m is 
the alkyl tail carbon chain length, m= 12 or 16 and R is a chain of hydrocarbon linkers attached 
to amino acids: R= Glycyl-Hexyl-lysine, Glycyl-Hexyl-Trilysine, Glycyl-Undecyl-lysine, 
Glycyl-Undecyl-Trilysine, Hexyl-Trilysine and Undecyl-Trilysine. The general chemical 
structure of these gemini surfactants is shown in Figure 1B. Methanol (HPLC grade purity, 
Fisher Scientific, Nepean, ON, Canada), Water (HPLC grade purity, Fisher Scientific, Nepean, 
ON, Canada),  and formic acid (purity 90%, EMD Chemicals Inc., Merck KGaA, Darmstadt, 
Germany) were used as solvents. 
 
Sample preparation  
Stock solutions of 3 mM gemini surfactants were prepared in methanol/water (50:50 v: 
v) containing 0.1% formic acid and stored at −20 ◦C. Each sample was further diluted 1000 X at 
the time of analysis using the same solvent. 
 
Mass spectrometric analysis 
Single stage MS analysis 
Gemini surfactants were analyzed using an AB SCIEX QSTAR® XL quadrupole 
orthogonal time of-flight hybrid mass spectrometer (QqToF-MS) equipped with an electrospray 
ionization (ESI) source (AB SCIEX, Redwood City, CA, USA). The instrument was operated in 
the positive ion mode with declustering potential of 100 V and focusing potential of 290 V. 
Sample aliquots were infused into the mass spectrometer at flow rate of 10 μL/min using an 
integrated Harvard syringe pump through a Turbo Ionspray Source, having a needle voltage of 
5500 V and a temperature of 80 °C. Nitrogen was used as the drying gas and ESI nebulizing gas. 
A two-point external calibration was performed prior to the analysis of gemini surfactants using 
two singly charged calibration standards: cesium iodide (CsI, m/z 132.9055, Sigma-Aldrich, 
Oakville, ON, Canada) and sex pheromone inhibitor iPD1 (m/z 829.5320, Bachem Bioscience 
Inc., PA, USA). 
 
Tandem mass spectrometric analysis 
Tandem mass spectrometric analysis of the tested gemini surfactants was performed 
using an AB SCIEX QTRAP® 4000 hybrid triple quadrupole–linear ion trap mass spectrometer 
(QqLIT-MS) equipped with a “Turbo V Ion Spray” ESI source (AB SCIEX, Redwood City, CA, 
USA). Collision-induced dissociation (CID) was conducted using nitrogen as the collision gas. 
The instrument was operated in the positive ion mode with declustering potential in the range of 
45–100 (optimized for each compound). Collision energy (CE) was also optimized for the range 
20–40 eV to induce fragmentation while maintaining the abundance of the precursor ion. 
Samples were infused into the instrument at flow rate of 10 μL/min by using a model 11 Plus 
syringe pump (Harvard Apparatus, Holliston, MA, USA). Ionspray voltage was set at 5500 V 
with source temperature of 300°C.  
It is noteworthy that the MS/MS analysis of the all tested peptide-modified gemini 
surfactants was also conducted using the QSTAR®. It generated similar MS/MS spectra to that 
produced by the QTRAP®, confirming the elemental compositions of the projected product ions 
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(Figure S1, Supplementary Material). However, MS/MS spectra acquired by the QTRAP® were 
more informative due to the ability of the linear ion trap to accumulate ions when performing the 
enhanced product ion scan. 
 
Multi-stage MS3 analysis 
MS3 analysis of the selected second-generation ions was conducted on the AB SCIEX 
QTRAP® 4000 instrument under the same optimized conditions mentioned above.  Excitation 
energy (AF2) was set at the range of 20–100 to obtain abundant fragments of the selected 
second-generation ions. 
 
Results and discussion 
Single-stage MS analysis 
Full scan ESI-QqToF-MS analysis of all tested peptide-modified gemini surfactants 
showed an abundant triply charged [M+H]3+ species (Table S1, Supplementary Material). In 
addition, some compounds with three terminal residues of amino acids showed a minor 
quadruply charged [M+2H]4+ species. The exact masses were assessed showing mass accuracies 
of less than 8 parts per million (ppm) mass error confirming the projected molecular structure of 
the tested gemini surfactants (Table S1, Supplementary Material). This mass accuracy was 
achieved by employing two-point external calibration prior to the analysis of the gemini 
surfactants. In fact, the accuracy of these measurements was similar to a recent work by our 
group which utilized internal calibration to assess mono-amino acid and di-amino acids 
substituted gemini surfactants [25]. 
Tandem mass spectrometric analysis 
The fragmentation behavior of peptide modified gemini surfactants was evaluated using 
low-energy CID-MS/MS employing ESI-QqLIT-MS instrument. Structural variation within the 
tested gemini surfactants, namely the number of amino acid residues, the length of the 
hydrocarbon tails and the length of the incorporated hydrocarbon linker drove the MS/MS 
dissociation behavior. In addition, MS/MS experiments yielded compound-specific product ions 
which authenticate the molecular structure of their precursor ions. Such product ions could be 
utilized as diagnostic ions for the qualitative and quantitative analysis of the evaluated gemini 
surfactants. 
 The MS/MS fragmentation behavior of peptide modified gemini surfactants showed 
remarkable differences compared to traditional gemini surfactants [23, 24]. This is mainly due to 
the insertion of peptide segments within the gemini surfactant spacer region, resulting in the 
formation of peptide-related dissociation characteristics. The number of terminal amino acid 
residues in the spacer seems to play a major role in determining the MS/MS fragmentation 
pattern; hence, MS/MS analysis will be discussed based on the number of terminal amino acids 
residues. The following sections include detailed discussion of the fragmentation patterns of the  
16-7N(C11-K3)-16 gemini surfactant as an illustrative example of compounds with the tri-
terminal amino acids residues as it has the most complex MS/MS spectra among all tested 
compounds. In addition, the MS/MS dissociation behaviour of 16-7N(G-C11-K)-16 is briefly 
discussed to highlight the fragmentation of gemini surfactants with a mono-terminal amino acid 
moiety. The major product ions for peptide modified gemini surfactants with tri-terminal amino 
acids residues and mono-terminal amino acid moiety are displayed in Tables 2 and 3 
respectively. 
MS/MS fragmentation pathway of the peptide modified gemini surfactants with tri-terminal 
lysine moieties  
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The fragmentation of the triply charged precursor ion of 16-7N(C11-K3)-16 gemini 
surfactant resulted in the formation of three initial diagnostic product ions that have their unique 
subsequent dissociation pathways (Figure 2, Table 1). Two initial product ions arise from the 
loss of one of the terminal lysine moieties producing either a doubly charged product ion (A) 
observed at m/z 538.54 or a triply charged product ion (B) observed at m/z 359.36. The third 
initial product ion results from the loss of a NH3 moiety generating a triply charged product ion 
(C) observed at m/z 396.38. The coexistence of the three initial product ions suggests a 
competition between different fragmentation mechanisms. While both ions (A) and (B) are 
formed by losing one of the terminal lysine residues from the precursor ion, they have different 
charge status implying the presence of different fragmentation mechanism for cleaving the amide 
bond.  
As indicated earlier, the presence of peptides within the gemini surfactants offered the 
compound protonated peptide characteristics, unlike conventional gemini surfactants [23, 24]. 
The dissociation of protonated peptides can be explained by the ‘mobile proton’ model: a 
comprehensive model that suggests a competition between charge-remote and charge-directed 
reactions to predict the fragmentation process [31-33]. Under low-energy conditions such as 
CID, charge-directed reactions are believed to be the major pathway for peptide dissociation in 
which bond cleavage is initiated by active involvement of the ionizing proton [34]. Thus, the 
location of the ionizing proton on the peptide chain could determine the fragmentation 
mechanism [33]. As such, the composition of the amino acids (the presence or absence of a basic 
residue), the sequence, size and charge state of the investigated peptide will play a crucial role in 
determining the MS/MS fragmentation pattern.  
The gemini surfactant 16-7N(C11-K3)-16 has a chain of three branched lysine moieties. 
Lysine is a basic amino acid that is most probably protonated at the ε-amino group of the side 
chain. Amid bond cleavage is initiated by nucleophilic attack by the lysine side chain on the 
amide bond [35, 36]. The first step of the reaction involves mobilization of the proton of the 
lysine side chain to the nitrogen of the C-terminal neighboring amide bond (Figure 3). 
Subsequently, nucleophilic attack by the lysine side chain on the carbon of the protonated amide 
bond leading to the cleavage of the amide bond and the formation of a protonated α-amino-ε-
caprolactam ion observed at m/z 129.10 (b1) (Figure 3). A complementary ion at m/z 538.5 
(product ion A) is formed rather than a neutral species as in the case of peptides due to the 
presence of quaternary amines that exist within the structure of gemini surfactants (Figure 1B, 
Figure 3).  
In fact, the formation of the product ion at m/z 129.10 is a characteristic of lysine 
containing peptides [35-37]. The loss of lysine through this mechanism explains the formation of 
product ion (A) the doubly charge compound, however, it does not explain the formation of 
product ion (B), the triply charged species of the same structure (Figure 2), suggesting the 
presence of alternative MS/MS dissociation mechanism.   
Two mechanisms can be proposed for the formation of the product ion (B) observed at 
m/z 359.36. The first could be explained by the  established fragmentation mechanism termed (ax 
- yx) which leads to integrated formation of ax and yx ions [38, 39]. This dissociation is focused 
on the cleavage of the amide bond and Cα –C amide bond resulting in the formation of protonated 
imine, carbon monoxide and product ion B (i.e. protonated C-terminal fragment) (Figure 4) [38]. 
Following the expulsion of the weakly bound carbon monoxide, a proton-bound dimer between 
the N terminal and the C-terminal fragments is formed. Under low-energy CID conditions, the 
formed dimer has a long lifetime allowing for numerous proton transfers among product ions to 
occur. As a result, the dimer is dissociated to form either product ion B (i.e. the y2 ion based on 
Roepstorff nomenclature for peptide fragmentation[40]) or ion a1 which is observed at m/z 
101.10 (Figure 4). It should be noted that ions B and a1 were only observed in gemini surfactants 
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with longer hydrophobic linker chain (C11) and not in shorter linker (C6) (Table 1). This is in 
agreement with previously reported behavior of mono and di- amino acid substituted gemini 
surfactants in which no ion B analogues was observed [25]. 
Alternative mechanism that could lead to the formation of product ion (B) is simply the 
same as that of product ion (A) (Figure 3), however; a proton transfer from the amide-nitrogen of 
the protonated α-amino-ε-caprolactam to the ε-amino group of the remaining lysine (c-terminus) 
is required. Csonka et al. indicated the possibility of such a dissociation to occur especially when 
the c-terminal part of the compound has high enough proton affinity to compete with the α-
amino-ε-caprolactam [36]. In the tested compound, the ε-amino group of the c- terminal has a 
higher pka value than the amide-nitrogen, thus it has higher proton affinity raising the possibility 
for the ion transfer to take place. As such, it is possible that two mechanisms are simultaneously 
involved in the formation of product ion (B).     
In addition to product ions A and B, Product ion (C) at m/z 396.38 results from the 
neutral loss of a (NH3) moiety (Figure S2, Supplementary Material; Figure 2). This is expected 
as protonated peptides under low-energy CID conditions often undergo neutral losses of small 
molecules such as water or ammonia [34]. The loss of ammonia has been reported mainly in 
basic amino acid residues such as lysine, arginine, asparagine and glutamine [34]. A charge-
directed fragmentation mechanism has been proposed for the elimination of ammonia from the 
lysine side chain [35]. As such, protonation of the side chain is required. Since ε-amino group is 
the most favored protonation site in lysine, mobilization of protons is not needed. Dookeran et al. 
demonstrated utilizing an α-15N protonated lysine that the loss of the NH3 moiety involves in 
particular the nitrogen of the side chain [37]. When lysine is located at the peptide N-terminus, 
like in the tested gemini surfactants, the loss of ammonia occurs via nucleophilic attack by the N-
terminal amino group resulting in the formation of pipecolic acid (Figure S2, Supplementary 
Material) [36]. It is noteworthy that the proposed fragmentation pathways forming the three 
initial product ions could involve either one of the two N-terminal lysine moieties, leading to 
identical product ions. In fact, the various observed ions could be a mixture of two species losing 
either lysine moiety terminal. Both losses will not affect the produced product ions that can still 
efficiently be used for both qualitative and quantitative applications.  
Dissociation of product ion A  
The dissociation of product ion (A) starts with the loss of the quaternary ammonium 
headgroup and the attached aliphatic tail resulting in the formation of two complementary ions: 
product ion (1) at m/z 270.31 a singly charged ion and a minor singly charged product ion (2) 
observed at m/z 806.76  (Figure 5, Table 1). In addition, a doubly charged species was observed 
at m/z 403.88 (2`) which shares the same molecular structure of product ion (2) albeit doubly 
charged. This suggests the existence of an alternative ion formation mechanism. It could be 
explained by a homolytic cleavage of the N-C bond between the quaternary ammonium 
headgroup and the hydrocarbon tail resulting in the neutral loss of the aliphatic tail (hexadec-1-
ene) and the formation of a doubly charged minor product ion at m/z 426.41(2*) (Figure 5).  In 
agreement with the previously observed behavior of mono and di- amino acid substituted gemini 
surfactants [25], the close proximity of the two positively charged head groups of  ions such as 
(2*) could make the ion relatively unstable which easily fragments  by the subsequent loss of a 
head group as dimethylamine leading to the formation of (2`) ion at m/z 403.88. Such a behavior 
was consistent among all the evaluated gemini surfactants. In fact, in some cases the intermediate  
ion (i.e. 2*) was abundant enough to enable for MS3 analysis that supported the projected 
molecular structure of this ion (2*) (Table S2, Supplementary Material). The formation of such 
unstable intermediate ions and their subsequent stable product ions (i.e. ion 2` in this case) was 
commonly noticeable in the various tested gemini surfactants. It will be referenced frequently in 
the text as an intermediate ion. 
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Product ion (2`) subsequently yields the formation of four product ions (Figure 5). The 
first involves the loss of the headgroup and the attached aliphatic tail (ion 1) at m/z 270.31 
producing a singly charged product ion (3) at m/z 537.44. A second ion is formed via the neutral 
loss of the aliphatic chain and the formation of intermediate doubly charged ion, as discussed 
above, at m/z 291.75 (ion structure is not shown) which easily loses the dimethylamine head 
group generating a doubly charged species (3`) at m/z 269.23. The third and fourth ions are 
formed as a result of eliminating the terminal lysine moiety leading to the formation of a singly 
charged ion (4) at m/z 678.66 and the corresponding doubly charged ion (4`) at m/z 339.83 
(dotted arrows originating from ion 403.8).  As shown in Figure 3, this cleavage is usually 
initiated by nucleophilic attack of the lysine side chain on the amide bond releasing m/z 129.10 
ion (b2) as a protonated α-amino-ε-caprolactam and forming product ion (4). Ion (4`) on the other 
hand could either result from the same mechanism as ion (4) but it requires a proton transfer 
from the protonated α-amino-ε-caprolactam to the complementary c-terminal ion or through the 
(ax - yx) peptide fragmentation mechanism (Figure 4). Unlike product ion (2`), fragmentation of 
the singly charged ion (2) produces only two product ions: ions (3) and (4) (Figure 5). 
Ion (3`) at m/z 269.23 undergoes neutral loss of ammonia forming pipecolic acid 
derivative compound at m/z 260.71 (5`) (Figure 5). Furthermore, (3`) loses another terminal 
lysine moiety forming a single-charged ion (6) at m/z 409.35 and a double-charged ion (6`) at 
m/z 205.18. Similar to ion (3`), ion (3) also eliminates an ammonia group producing ion (5) at 
m/z 520.42 and loses a lysine moiety to produce ion (6). Ion (6) can also be formed via the loss 
of alkyl tail from ion (4) as well as ion (4`); the latter can additionally yield ion (6`) as shown in 
Figure 5. Finally, ions (5) and (5`) can also yield the formation of product ion (6) through the 
loss of the pipecolic acid ring (Figure 5). It can be speculated that this loss occurred by the 
mobilization of the proton from the pipecolic acid ring to the nitrogen of the amide bond 
followed by nucleophilic attack either by the carbonyl group releasing pipecolic acid which was 
observed at m/z 112.07 or by the pipecolic acid ring’s amine resulting in opening the ring and 
forming caprolactam ion which was also observed at m/z 114.09 (Figure 5).  
Product ion (6`) experiences loss of ammonia group forming ion (7) at m/z 196.67 and 
eliminates the last lysine moiety forming ion (8) at m/z 281.26. It should be noted that ion (8) at 
m/z 281.26 was also produced by ion (6); however, MS3 analysis did not show any second 
generation product ions at m/z 129.10, which corresponds to the elimination of lysine as a 
protonated α-amino-ε-caprolactam (Table S2, Supplementary Material). This finding supports 
the theory of the proton transfer from the protonated α-amino-ε-caprolactam to the c-terminal 
fragment ion that we proposed earlier as a possible mechanism to justify the formation of 
product ion B.  
 
Dissociation of product ion B  
Product ion (B) dissociates via two fragmentation pathways; firstly by the loss of an 
NH3 moiety from the terminal lysine producing pipecolic acid derivative, product ion (9) at m/z 
353.68 (Figure 6, Table 1). The second product ion results from the loss of the terminal lysine 
amino acid residue (observed at m/z 129.10 [b2]) by amide bond cleavage forming a doubly 
charged product ion (10) at m/z 474.49.  Elimination of the pipecolic acid part of ion (9) also 
leads to the formation of ion (10) which subsequently dissociates by eliminating the last terminal 
lysine, forming ion (11) observed at m/z 410.44.  Furthermore, ion (10) loses the tail region and 
the attached head forming the previously mentioned singly and doubly charged ions designated 
as (4) and (4`). As it can be seen, the complexity of the MS/MS spectra supports the notion that 
some ions may be formed from various product ions as in the case of the product ions (4) and 
(4`). Such observation is supported by second generation MS3 analysis (Table S2, Supporting 
Material). Both of these ions further dissociate as shown in Figure 6. Ion (11) also loses the 
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aliphatic tail and the attached head group yielding ion (12) and (12`) at m/z 550.57 and m/z 
275.79 respectively supported by second generation MS3 analysis (Table S2, Supplementary 
Material). Both ions subsequently eliminate the remaining dimethylalkenammonium ion forming 
the product ion (8) at m/z 281.26 (Figure 6).  
Dissociation of product ion C  
Product ion (C) was the source of six product ions (Figure 7) which is much more 
complex than product ions A or B. This is expected since product ion C retains the same 
structural backbone of the precursor ion with the simple loss of NH3 moiety. The first two 
product ions arise from the loss of pipecolic acid re-forming product ions (A) or (B) which was 
confirmed by MS3 analysis (Table S2, Figure S3, Supplementary Material). On the other hand, 
cleavage of the peptide bond of the lysine with intact side chain resulted in the formation of ions 
9 and 9` observed at m/z 353.68 and m/z 530.02 (Figure 7, Table 1) respectively which differs 
only in the charge state due to variations in the formation mechanisms as disused earlier in 
details in the section entitled “Dissociation of product ion A”. Interestingly, MS3 analysis of ion 
(C) revealed that product ions (A) and (B) were of lower abundance than product ions 9 and 9` 
(Figure S3, Supplementary Material). This could be attributed to the ease of the cleavage of the 
amide bond linked to the lysine side chain ε-amino group in comparison to the loss of pipecolic 
acid.  
Product ion (C) can also eliminates another ammonia group from the second terminal 
lysine producing a triply charge ion (13) observed at m/z at 390.70 (Figure 7, Table 1). Since the 
elimination of the ammonia is charge-directed, mobilization of the proton from the pipecolic acid 
ring to the lysine ε-amino group is required. Ion (13) subsequently loses one of the pipecolic 
acids yielding the previously mentioned ions (9) and (9`) which was confirmed by second 
generation MS3 analysis (Table S2). Finally, product ion C undergoes a neutral loss of the 
aliphatic tail forming an unstable intermediate at m/z 321.63 (not shown) which easily loses 
dimethylamine group forming a triply charged ion (14) at m/z 306.61. Similar to past 
observation, such an intermediate ion was occasionally observed and its genesis was confirmed 
by MS3 analysis.  
Ion (14) eliminates the remaining ammonium headgroup and the associated aliphatic tail 
producing the product ion (15) at m/z 324.76. It also undergoes neutral loss of the tail through 
hemolytic cleavage of the N-C bond forming, as above, unstable intermediate at m/z 231.86 that 
subsequently losses the head group yielding ion (15`) at m/z 216.84. Ion (16) observed at m/z 
300.94 is also produced from ion (13) after losing the dimethylalkenammonium ion and from ion 
(14) after the neutral loss of ammonia which was confirmed by MS3 analysis (Figure 7, Table 
S2). Ion (16) follows same pathway as ion 14 forming ion (17) at m/z 316.25 and ion (17`) at m/z 
211.17. Both ion 17 and 17` was generated by loss of ammonia from ions 15 and 15`. Ions 15, 
15`, 17 and 17` further cleaved various amid bonds producing smaller structures product ions as 
illustrated in Figure 7. 
 Ions 9 and 9` follow similar fragmentation pattern as ion (13), firstly by losing one of 
the dimethylalkenammonium  ions then by eliminating the second one (Figure 7, Table 1).The 
produced product ions later fragmented to smaller ions in a similar fashion by cleaving the amide 
bond and/or ejecting lysine moieties as illustrated in Figure 7. 
In order to support the proposed fragmentation pathways of the peptide-modified 
gemini surfactants with tri-terminal lysine moieties, isotopically labeled analogues were 
evaluated. This include compounds 16-7N(G-C11-KD-K2)-16 and 16-7N(G-C6-KD-K2)-16 where 
KD is a deuterated lysine moiety bearing four deuterium atoms. The MS/MS analysis revealed an 
increased m/z values in the product ions containing the deuterated lysine such as product ions 
(A), (B) and (C) (Figure S4, Supplementary Material). Moreover, fragment ions (8), (11), (12) 
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and (12`) that bear no deuterated region showed identical m/z values, confirming the proposed 
fragmentation pathway (Figure S4, Supplementary Material). 
MS/MS fragmentation pathway of the peptide modified gemini surfactants with mono-terminal 
lysine moiety 
Gemini surfactant 16-7N(G-C11-K)-16 is used as an illustrative example of peptide 
modified gemini surfactants functionalized with single terminal lysine moiety (Figure 8). Similar 
to the fragmentation pathway of 16-7N(C11-K3)-16 gemini surfactant, dissociation of 16-7N(G-
C11-K)-16 compound started with either the elimination of the lysine moiety and/or the neutral 
loss of amino group. Elimination of the lysine residue through the cleavage of the amide bond 
produced ion (A), a doubly charged product ion observed at m/z 438.95, and released its 
complimentary ion (b1) at m/z 129.10 as a protonated α-amino-ε-caprolactam (Figure 8, Table 2). 
Unlike 16-7N(C11-K3)-16 gemini surfactants, the formation of a triply charged product ion after 
the elimination of the lysine residues from 16-7N(G-C11-K)-16 was not observed. This is 
possibly due to the higher proton affinity of the α-amino-ε-caprolactam compared to the c-
terminal product ions. A charge-directed loss of the lysine ε-amino group from the precursor ion 
resulted in the formation of pipecolic acid derivative product ion (B) at m/z 329.99 which can 
subsequently eradicate the pipecolic acid ring forming ion (A) (Figure 8). 
As indicated earlier, product ion (A) undergoes the loss of the dimethylalkenammonium  
ion (1) generating both a single-charged product ion (2) at m/z 607.59 and a double-charged 
product ion (2`) at m/z 304.30 (Figure 8, Table 2). Both product ions experience a loss of the last 
dimethylalkenammonium  ion producing product ion (3) at m/z 338.28. In addition, ion (2`) 
produced ion (3`), the doubly charged analog of ion (3).  
Ion (B) also loses ion (1) producing ion (4) at m/z 240.22 which either eliminates the 
last dimethylalkenammonium  ion generating ion (5) at m/z 225.18 and/or removes the pipecolic 
acid ring resulting in the formation of ion (2`) (Figure 8, Table 2). Further dissociations of ion 
(5) are self-explanatory resulting in the production of ion (3) and (3`). Similar to other 
compounds, the genesis and structures of all ions observed in Figure 8 were confirmed by MS3 
analysis (data not shown).   
 
Universal MS/MS fragmentation pattern of the novel peptide modified gemini surfactants 
Similarities in the fragmentation behaviour of the peptide modified gemini surfactants resulted in 
the establishment of a universal MS/MS fragmentation pattern (Figure 9) that can be applied to 
any related structure. The universal fragmentation pathway begins with both the cleavage of the 
peptide bond forming a doubly charged product ion (A) and the neutral loss of the lysine’s ε-
amino group producing pipecolic acid derivative product ion (B).  
Two dissociation pathways are proposed for product ion (A). First, a loss of one quaternary 
ammonium headgroup and the attached aliphatic tail producing two complimentary ions: 
dimethylalkenammonium  product ion (1) and the singly charged product ion (2). The second 
pathway occurs via homolytic cleavage of the N-C bond between the quaternary ammonium 
headgroup and the hydrocarbon tail resulting in the neutral loss of the aliphatic tail and the 
production of a doubly charged intermediate ion that easily eradicates the dimethylamine head 
group, probably due to the close proximity of the two positively charged head groups, generating 
product ion (2`). In some cases the intermediate ion was abundant enough to conduct MS3 
analysis to support proposition. Both ions (2) and (2`) also undergo subsequent loss of 
dimethylalkenammonium ion forming ions (3) and (3`) (Figure 9).  
On the other hand, ion (B) dissociates by the loss of dimethylalkenammonium  ion forming a 
triply charged ion (4) which subsequently eliminates another dimethylalken ammonium ion to 
produce ion (5). Product ions (B), (4) and (5) produced ions (A), (2`) and (3`) respectively 
through the removal of the pipecolic acid ring as illustrated in Figure 9. 
10 
 
 
Conclusion  
In this work, we utilized ESI-QqToF-MS and ESI-QqLIT-MS to study the CID-MS/MS 
fragmentation behaviour of eleven novel peptide-modified gemini surfactants. Exact mass 
measurements confirmed the projected molecular composition of the evaluated compounds 
showing mass accuracies of less than 8 ppm. In addition, tandem mass spectrometric analysis 
generated compound-specific product ions authenticating the chemical structure of their 
precursor ions. The genesis of these product ions was further confirmed by MS3 analysis (Table 
S2, Supplementary Material), allowing for the development of fragmentation pattern that could 
be used as a fingerprint for accurate identification of the tested compounds.  
In general, the MS/MS dissociation was centered on the attached amino acids in which 
peptide bonds were cleaved for the generation of diagnostic product ions. Furthermore, neutral 
loss of an ammonia group from the amino acid side chain was dominant within the evaluated 
structures. Elimination of one or both of the quaternary ammonium headgroups and the attached 
aliphatic tail was also observed. It should be noted that the number of terminal amino acid 
residues in the spacer and the length of the inserted hydrocarbon linker affected the dissociation 
behaviour. For example, the formation of the triply charged initial product ions after eliminating 
a terminal lysine residue was only observed in gemini surfactants with longer hydrophobic linker 
chain (C11) and with tri-terminal amino acids residues. Nevertheless, similarities in the 
fragmentation behaviour among all the tested gemini surfactants resulted in the production of a 
universal fragmentation pattern as illustrated in Figure 9. This universal fragmentation pattern 
can be utilized to predict the dissociation behaviour of new compounds with similar general 
structural features. In addition, it will be utilized for the development of qualitative and 
quantitative MS-based methods to probe the fate and biodistribution of topically applied 
therapeutic gemini surfactant formulations. We are currently quantitatively evaluating the 
distribution of lead gemini surfactants within skin tissues for therapeutic applications. This data 
will be reported upon completion.  
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 Figure 1. (A) Prototype of gemini surfactants showing the two ionic head groups, hydrocarbon 
tails and the spacer and (B) schematic representation of the general structure of the tested peptide 
modified gemini surfactants.  
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Table 1. Precursor ions and product ions observed during MS/MS analysis of [M+H] 3+ ions of the peptide modified gemini surfactants with tri-terminal lysine moieties. 
 
 Gemini surfactants  12-7N(G-C11-
K3)-12 
16-7N(G-C11-
K3)-16 
12-7N(G-C6-
K3)-12 
16-7N(G-C6-
K3)-16 
12-7N(C11-
K3)-12 
16-7N(C11-
K3)-16 
12-7N(C6-
K3)-12 
16-7N(C6-
K3)-16 
 m/z m/z m/z m/z m/z m/z m/z m/z 
 Precursor ions 383.6895 421.0633 360.3344 397.7076 364.6828 402.0593 341.3257 378.7015 
Ion # Product ions m/z m/z m/z m/z m/z m/z m/z m/z 
A [M–C6H13N2O]2+ 510.98 567.04 475.94 532.37 482.47 538.54 447.43 503.50 
B (y2) [M–C6H12N2O]3+ 340.99 378.37                                                                                                                                                       321.98 359.36   
C [M–NH3]3+ 378.01 415.39 354.65 392.03 359.01 396.38 335.65 373.02 
bx C6H13N2O 129.10 129.10 129.10 129.10 129.10 129.10 129.10 129.10 
a1 C5H13N2 101.10 101.10     101.10 101.10     
1 Dimethylalkenammonium  214.25 270.31 214.25 270.31 214.25 270.31 214.25 270.31 
2 [M–( bx)-ion(1)]+ 807.71 863.78 737.63 793.70 750.69 806.76 680.62 736.68 
2` [M–( bx)-ion(1)]2+ 404.36 432.39 369.32 397.35 375.85 403.88 340.81 736.68 
3 [M–( bx)-2 ion(1)]+ 594.47 594.47 524.40 524.40 537.44 537.44 467.37 467.37 
3` [M–( bx)-2 ion(1)] 2+ 297.74 297.74 262.70 262.70 269.23 269.23 234.19 234.19 
4 [M– 2(bx)-ion(1)]+ 679.62 735.68 609.54 665.59 622.60 678.66 552.52 608.58 
4` [M– 2(bx)-ion(1)] 2+ 340.31 368.19 305.27 333.30 311.80 339.83 276.76 304.80 
5 [M–( bx)-(NH3)-2 ion(1)]+ 577.44 577.44 507.36 507.36 520.42 520.42 450.34 450.34 
5` [M–( bx)-(NH3)-2 ion(1)]2+ 289.22 289.22 254.18 254.18 260.71 260.71 225.67 225.67 
6 [M– 2(bx)-2 ion(1)] + 466.94 466.94 396.30 396.30 409.35 409.35 339.27 339.27 
6` [M– 2(bx)- 2 ion(1)]2+ 233.69 233.69   205.18 205.18   
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7 [M–2(bx)-(NH3)-2ion(1)] 2+ 225.18 225.18 190.14 190.14 196.67 196.67 161.63 161.63 
8 [M–3(bx)- 2 ion(1)] + 338.27 338.27 268.19 268.19 281.26 281.26 211.18 211.18 
9 [M–( bx)-(NH3)] 3+ 335.31 372.69 311.96 349.33 316.31 353.68 292.95 330.32 
9` [M–( bx)-(NH3)] 2+ 502.47 558.53 467.43 523.49 473.96 530.02 438.92 494.98 
10 [M–2(bx)] 2+ 446.94 503.00 411.90 467.96 418.43 474.49 383.39 439.45 
11 [M–3(bx)] 2+ 382.89 438.95 347.85 403.91 354.38 410.44 319.34 375.40 
12 [M–3(bx)- ion(1)] + 551.52 607.59 481.44 537.51  494.50 550.57 424.43  480.49 
12` [M–3(bx)- ion(1)] 2+ 276.27 304.30 241.23 269.26 247.75 275.79 212.71  240.75 
13 [M–2(NH3)] 3+ 372.34 409.71 348.97 386.62 353.33 390.70 329.97 367.35 
14 [M–(NH3)-ion(1)] 3+ 306.93 325.62 283.57 302.26 287.92 306.61 264.57 283.25 
15 [M–(NH3)-2 ion(1)]2+ 353.27 353.27 318.23 318.23 324.76 324.76 289.72 289.723 
15` [M–(NH3)-2 ion(1)] 3+ 235.85 235.85 212.49 212.49 216.84 216.84 193.48 193.48 
16 [M–2(NH3)-ion(1)] 3+ 301.26 319.94 277.90 296.58 282.25 300.94 258.89 277.58 
17 [M–2(NH3)-2 ion(1)] 2+ 344.76 344.76 309.72 309.72 316.25 316.25 281.21 281.21 
17` [M–2(NH3)-2 ion(1)] 3+ 230.17 230.17 206.82 206.82 211.17 211.17 187.81 187.81 
18 [M–( bx)-(NH3)- ion(1)] + 790.69 846.75  720.61                                                                                                                                                                                                                                                                                                                           776.67 733.67 789.73 663.59 719.65
 
18` [M–( bx)-(NH3)- ion(1)] 2+ 395.85 423.87 360.81 388.84 367.33 395.37 332.30 360.33 
18`` [M–( bx)-(NH3)- ion(1)] 3+ 264.23 282.92 240.87 259.56 245.23 263.91 221.87 240.55 
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Table 2. Precursor ions and product ions observed during MS/MS analysis of [M+H] 3+ ions of the peptide modified gemini surfactants with mono-terminal lysine moiety.  
 
 
  
 Gemini surfactants 16-7N(G-C11-K)-16 12-7N(G-C6-K)-12 16-7N(G-C6-K)-16 
  m/z m/z m/z 
 Precursor ions 335.6693 274.9356 312.3098 
Ion # Product ions m/z m/z m/z 
A [M–C6H13N2O]2+ 438.95 347.85 403.91 
B [M–NH3]3+ 329.99 269.26 306.63 
b1 C6H13N2O 129.10 129.10 129.10 
1 Dimethylalkenammonium  270.31 214.25 270.31 
2 [M–( b1 )- ion(1)] + 607.59 481.44 537.51 
2` [M–( b1 )- ion(1)] 2+ 304.30 241.23 269.26 
3 [M–( b1 )-2 ion(1)] + 338.28 268.20 268.20 
3` [M–( b1)-2 ion(1)] 2+ 169.64 134.60 134.60 
4 [M–(NH3)- ion(1)] 3+ 240.22 198.18 216.86 
5 [M–(NH3)- 2 ion(1)] 2+ 225.18 190.14 190.14 
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Figure 2. The ESI-QqLIT-MS/MS spectrum of 16-7N(C11-K3)-16 as a representative example of gemini surfactants with tri-terminal lysine moieties. Ions were labelled as 
designated in Figures 5-7. Strcture of the three initial product ions are shown as an insert (top).
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Figure 3.  The proposed mechanism for the formation of product ion (A) and (b1): amide bond 
cleavage initiated by lysine side chain  
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Figure 4.  The proposed mechanism for the formation of product ion (B) and (a1):  cleavage of 
Cα –C amide bond through ax - yx fragmentation pathway.  
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Figure 5. Proposed MS/MS product ions generated form product ion (A) at m/z 538.54 of 16-
7N(C11-K3)-16 gemini surfactant. Product ion 2* is an intermediate ion.  
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Figure 6. Proposed MS/MS product ions generated form product ion (B) at m/z 359.36 of 16-
7N(C11-K3)-16 gemini surfactant. 
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Figure 7. Proposed MS/MS product ions generated form product ion (C) at m/z 396.38 of 16-7N(C11-K3)-16 gemini surfactant.  
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Figure 8. (A) The ESI-QqLIT MS/MS spectrum of 16-7N(G-C11-k)-16 as a representative 
example of gemini surfactants with mono-terminal lysine moiety and (B) the proposed MS/MS 
fragmentation pattern.  
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Figure 9. Universal MS/MS fragmentation pattern for peptide modified gemini surfactants.  
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